This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zee RY and Ridker PM (2002) Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 162: 217–219
Kluft C and de Maat MP (2003) Genetics of C-reactive protein: new possibilities and complications. Arterioscler Thromb Vasc Biol 23: 1956–1959
Freedman LS et al. (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167–178
Ridker PM and JUPITER Study Group (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 108: 2292–2297
van de Ree MA et al. (2003) Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166: 129–135
Acknowledgements
The synopsis was written by Jenny Buckland, Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C Kluft has received research grants from Pfizer.
Rights and permissions
About this article
Cite this article
Kluft, C. Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events?. Nat Rev Cardiol 2, 244–245 (2005). https://doi.org/10.1038/ncpcardio0196
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0196